

## **Product** Data Sheet

# p-Coumaric acid-d<sub>6</sub>

Cat. No.: HY-N0351S1 2708298-33-1 Molecular Formula:  $C_9H_2D_6O_3$  Molecular Weight: 170.19

Target: Endogenous Metabolite

Pathway: Metabolic Enzyme/Protease

Storage: Powder

Powder  $-20^{\circ}$ C 3 years  $4^{\circ}$ C 2 years In solvent  $-80^{\circ}$ C 6 month

nt -80°C 6 months -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (587.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	5.8758 mL	29.3789 mL	58.7579 mL
	5 mM	1.1752 mL	5.8758 mL	11.7516 mL
	10 mM	0.5876 mL	2.9379 mL	5.8758 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

p-Coumaric acid-d<sub>6</sub> is the deuterium labeled p-Coumaric acid (HY-N0351). p-Coumaric acid is the abundant isomer of cinnamic acid which has antitumor and anti-mutagenic activities[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs $^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

In Vitro

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Jaganathan SK, et al. Events associated with apoptotic effect of p-Coumaric acid in HCT-15 colon cancer cells. World J Gastroenterol. 2013 Nov 21;19(43):7726-34.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com